Skip to main content
HealthReportedMedium
4.7

CG Oncology bladder cancer immunotherapy cuts recurrence risk by 68%

CG Oncology reported that its investigational immunotherapy for bladder cancer reduced the risk of tumor recurrence by 68% in a clinical trial. The results, if confirmed, could shift treatment paradigms for certain patients. The data are from a company press release and have not been independently verified.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works

STAT News3 days agoUSengCredibility 19%View source

Score Breakdown

Mosaic Score4.7
Model confidence0.5
Significance0.5
Source credibility0.2

Intelligence Tags

Entities

United Statescountry
Source

Related signals

8 found